 |
| TWU’s President Bob Kuhn practices for the Tour de Fox happening this Saturday, August 20, 2016, in Langley, BC. Trinity Western University (CNW Group/Trinity Western University)
LANGLEY, BC, CNW/ - Trinity Western University is hosting the 2016 Pacific Northwest Tour de Fox, a Michael J. Fox Foundation fundraiser for Parkinson's research on August 20, 2016.
The university is not only hosting the event. TWU's president, Bob Kuhn, who has lived with Parkinson's since 2006, will ride 35 miles (about 56 km) in the Tour de Fox as the captain of Team TWU.
"Many of the 5,000,000+ people who have Parkinson's disease suffer a lot more than I do," wrote Kuhn on his Tour de Fox page. "Many feel hopeless and incredibly discouraged. They need to have hope. So it is for those people that I want to do all I can to help find a cure. I'm riding in the Tour de Fox as part of Team TWU because it reminds me that there is still much that I can do. It reminds me to appreciate that I am alive."
"Research for Parkinson's disease is close to our hearts at Trinity Western University," said Amy Robertson, a university spokesperson. "Our president, Bob Kuhn, inspires us every day, and we'd like to rally behind him. TWU is an official sponsor of the Tour de Fox ride, but more importantly, our community is a family, so we're building Team TWU to ride with Bob and make a difference."
Thus far, Team TWU, at 11 riders and counting, has raised $7,145, putting them in second place among all the teams riding in the Pacific Northwest cycling event thus far.
Participants raise funds and choose either a 10-mile, 35-mile, or 70-mile bicycle loop, all of which begin and end on the TWU campus in Langley. All funds will be matched by a generous donor and will support programs to find a cure for Parkinson's disease.
Kuhn has been a longtime supporter of Parkinson's research. In 2014, he raised $24,000 for the Michael J. Fox Foundation through the 50 CC motorcycle ride.
Participation details: (https://tourdefox.michaeljfox.org/pacificnorthwest/Account/Register)
Media and other resources
Fast facts: Parkinson's disease Source: Michael J. Fox Foundation
SOURCE Trinity Western University
Image with caption: "TWU’s President Bob Kuhn practices for the Tour de Fox happening this Saturday, August 20, 2016, in Langley, BC. Trinity Western University (CNW Group/Trinity Western University)". Image available at: http://photos.newswire.ca/images/download/20160815_C8359_PHOTO_EN_753150.jpg
For further information: Media inquiries, Amy Robertson, Associate Director, Media and PR, amy.robertson@twu.ca, 604-753-9259
|
Monday, August 15, 2016
Trinity Western University rallies to host and support Tour de Fox for Parkinson's research
Aug. 15, 2016
Gaming Camera Could Aid Multiple Sclerosis Treatment
Aug. 15, 2016
 |
| Gholami captured the movement of 10 MS patients and 10 members of an age-and-sex-matched control group using the Kinect device. The MS patients had previously been assessed for gait abnormalities using the traditional clinician method. NeuroscienceNews.com image is for illustrative purposes only.
Summary: A common game system camera could be used as an effective means of evaluating gait and walking problems in people with multiple sclerosis.
Source: McGill University.
3-D depth-sensing camera shown to measure walking difficulties.
A commonly used device found in living rooms around the world could be a cheap and effective means of evaluating the walking difficulties of multiple sclerosis (MS) patients.
The Microsoft Kinect is a 3D depth-sensing camera used in interactive video activities such as tennis and dancing. It can be hooked up to an Xbox gaming console or a Windows computer.
A team of researchers led by McGill University postdoctoral fellow Farnood Gholami, supervised by Jozsef Kövecses from the Department of Mechanical Engineering and Centre for Intelligent Machines, collaborated with Daria Trojan, a physiatrist in the Department of Neurology and Neurosurgery working at the Montreal Neurological Institute and Hospital, to test whether the Kinect could detect the differences in gait of MS patients compared to healthy individuals.
In current clinical practice, the walking movement of MS patients is usually assessed by their doctors, and subjective evaluations may distort results: two different clinicians may give the same patient different evaluations. Using a camera that detects movement and computer algorithms that quantify the patients’ walking patterns can reduce potential for human error.
Gholami captured the movement of 10 MS patients and 10 members of an age-and-sex-matched control group using the Kinect device. The MS patients had previously been assessed for gait abnormalities using the traditional clinician method.
Using the data, the team then developed computer algorithms that quantified gait characteristics of MS patients and healthy people. The investigators found that gait characteristics measured with the Kinect camera and analyzed with the developed algorithms were reproducible when assessed at one visit and were different between MS patients and the healthy individuals. Moreover, the gait characteristics of MS patients obtained by the algorithm were correlated with clinical measures of gait. In addition, the algorithms could mathematically define the characteristics of gait in MS patients at different severity levels, accurately determining his/her level of gait abnormality.
Gholami says he became interested in using motion capture technology for clinical purposes as a PhD student, but the equipment he was using at the time was very expensive, difficult to use, and non-portable, making widespread clinical use prohibitive. The Kinect device gave him an inexpensive tool to use that appears to be still accurate enough to do the job.
“This tool may help the clinician provide a better diagnosis of gait pathology, and may be used to observe if a prescribed medication has been effective on the gait of the patient or not,” he says. “Our developed framework can likely be used for other diseases causing gait abnormalities as well, for instance Parkinson’s disease.”
Trojan says the tool could be useful “to assess treatment effects of certain interventions such as rehabilitation or medication, and to document MS disease progression as reflected by gait deterioration. It may also be useful as a measure in clinical trials.”
Gholami says the next step is to conduct a study with a larger group of MS patients, including evaluation in a gait laboratory, using a newer version of the Kinect device that promises to improve accuracy.
This work was completed in collaboration with Behnood Gholami at AreteX Systems Inc., Hoboken, NJ, and Wassim M. Haddad at Georgia Institute of Technology, Atlanta, GA.
ABOUT THIS NEUROLOGY RESEARCH ARTICLE
Funding: This research was made possible with funds from the Natural Sciences and Engineering Research Council of Canada.
Source: Shawn Hayward – McGill University
Image Source: This NeuroscienceNews.com image is for illustrative purposes and is licensed CC BY SA 3.0.
Original Research: Abstract for “A Microsoft Kinect-Based Point-of-Care Gait Assessment Framework for Multiple Sclerosis Patients” by Farnood Gholami; Daria Trojan; Jozsef Kovecses; Wassim Haddad; and Behnood Gholami in IEEE Journal of Biomedical and Health Informatics. Published online July 21 2016 doi:10.1109/JBHI.2016.2593692
http://neurosciencenews.com/gaming-glasses-ms-4851/
|
UH biomedical engineer pursues nerve regeneration
Aug. 15, 2016 - UNIVERSITY OF HOUSTON
NIH grant funds work to spur regeneration in nervous system
 |
| Mohammad Abidian will work to spur nerve regeneration in the peripheral nervous system
A biomedical engineer from the University of Houston will use a $1.2 million grant from the National Institutes of Health to determine how best to spur nerve regeneration in the nervous system.
The nervous system functions as the body's electrical system, a collection of specialized cells that transmit signals between different parts of the body. But injuries and certain degenerative diseases - including Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis - can interrupt that communication, posing a challenge for scientists seeking ways to return the body's nervous system to healthy function.
Mohammad Reza Abidian, associate professor of biomedical engineering, said surgical repairs can sometimes bridge small gaps between damaged nerves - typically gaps of less than one centimeter - but that isn't an option for more severely damaged nerves. Instead, scientists are seeking to spur nerve regeneration in ways that can mend the breech.
"Nature can regulate nerve regeneration, but fully functional recovery may require additional steps," he said. "We want to provide cues for the axons to regenerate along specific pathways."
The nervous system is made up of the central nervous system - the brain and spinal cord - and the peripheral nervous system, which communicates with the central nervous system through axons, transmitting instructions from the brain to the arms and legs, for example. Abidian's work under this grant will focus on directing axons to regenerate along specific pathways.
Axons search out signals from their physiological environment to determine which direction to grow, and Abidian said scientists know that those signals can be disrupted by illness or injury. To overcome that disruption, researchers need to understand how shifts in the concentration of chemicals or other physical factors, known as the gradient, affect axonal growth, as well as how that gradient should be shaped. Abidian and his lab will develop a technology platform that will allow them to test various gradient shapes, individually and in combination, and then do testing in the lab and in animal studies to determine how those changes affect axonal regeneration.
The work is a continuation of research he began in graduate school; he started working with the peripheral nervous system during a post-doctoral fellowship at the University of Michigan.
His expertise includes developing implantable micro and nanodevices that can safely interact with the nervous system, and while his research group doesn't target specific diseases, researchers there create materials and devices to solve specific neurological problems.
Abidian said the work in axonal regeneration would be useful for repairing the damage caused by neurodegenerative diseases or injuries, but it also has applications for the field of neural prosthetics, devices that can artificially restore lost function.
http://www.eurekalert.org/pub_releases/2016-08/uoh-ube081516.php
|
New research sheds light on the role of proteins and how synapses work
Aug. 15, 2016
 |
| Left hemisphere of J. Piłsudski's brain, lateral view. Credit: public domain |
Synapses are the power junctions that allow living creatures to function. Popularly associated with learning and memory, they play a more fundamental role in our existence by regulating everything from breathing, sleeping and waking and other bodily functionsoss of synapses and synapse function sit at the heart of a number of diseases, not just neurodegenerative examples such as dementia and Parkinson's disease but also conditions such as diabetes. We do not fully understand how synapses work, but new research published on Nature Neuroscience's website has shed new light on the role of proteins in the way in which synapses maintain their signaling.
The research has been carried out by an international team of scientists from: the Institute for Biology/Genetics and the Institute of Chemistry and Biochemisty/Structural Biochemistry, Freie Universität Berlin; NeuroCure, Cluster of Excellence, Charité Universitätsmedizin, Berlin; Molecular and Theoretical Neuroscience, Leibniz-Institut für Molekulare Pharmakologie, Berlin; Department of Nanobiophotonics, Max Planck Institute for Biophysical Chemistry, Göttingen; Plymouth University Peninsula Schools of Medicine and Dentistry; the Department of Genetics, University of Cambridge, and; the Institute of Pharmaceutical Sciences, Pharmaceutical Chemistry, University of Graz, Austria.
The team used genetics like a scalpel blade to remove individual proteins from the synapse to identify their different roles within the synapse, and how they maintain synaptic transmission. They used synapses from the fruit fly drosophila, which compares remarkably closely to synapses in humans.
The team used genetics like a scalpel blade to remove individual proteins from the synapse to identify their different roles within the synapse, and how they maintain synaptic transmission. They used synapses from the fruit fly drosophila, which compares remarkably closely to synapses in humans.
 |
| The findings of the study will prove invaluable to other research studies examining the role of synapse function in the diagnosis and treatment of neurodegenerative and other diseases. NeuroscienceNews.com image is for illustrative purposes only.(http://neurosciencenews.com/synapses-proteins-neuroscience-4844/) |
The results showed that two variations of a protein called Unc13 work separately to regulate synaptic transmission. The study is the first to show how the different forms of this protein work.
The findings of the study will prove invaluable to other research studies examining the role of synapse function in the diagnosis and treatment of neurodegenerative and other diseases. A greater understanding of how synapses work may also find a role in identifying unexpected drug targets for specific diseases.
Dr. Iain Robinson, Associate Professor in Neurosciences at Plymouth University Peninsula Schools of Medicine and Dentistry is part of the international research team on this study. He said: "Using a combination of genetics and state of the art imaging allows us to dissect the function of synapses which are used to convey messages in the brain. We have moved another step nearer to understanding the mechanisms employed by synapses and created knowledge which could play a vital role in research projects with the potential to discover breakthroughs in the diagnosis and treatment of a wide range of debilitating and life-changing diseases."
Journal reference: Nature Neuroscience
Provided by: University of Plymouth
http://medicalxpress.com/news/2016-08-role-proteins-synapses.html
How Parkinson’s Alters Brain Activity Over Time
Summary: Researchers have identified how specific brain areas change over time in patients with Parkinson’s disease.
Source: NIH/NINDS.
Tracking neural changes could help researchers test therapies that slow disease progression.
Neuroscientists peered into the brains of patients with Parkinson’s disease and two similar conditions to see how their neural responses changed over time. The study, funded by the NIH’s Parkinson’s Disease Biomarkers Program and published in Neurology, may provide a new tool for testing experimental medications aimed at alleviating symptoms and slowing the rate at which the diseases damage the brain.
“If you know that in Parkinson’s disease the activity in a specific brain region is decreasing over the course of a year, it opens the door to evaluating a therapeutic to see if it can slow that reduction,” said senior author David Vaillancourt, Ph.D., a professor in the University of Florida’s Department of Applied Physiology and Kinesiology. “It provides a marker for evaluating how treatments alter the chronic changes in brain physiology caused by Parkinson’s.”
Parkinson’s disease is a neurodegenerative disorder that destroys neurons in the brain that are essential for controlling movement. While many medications exist that lessen the consequences of this neuronal loss, none can prevent the destruction of those cells. Clinical trials for Parkinson’s disease have long relied on observing whether a therapy improves patients’ symptoms, but such studies reveal little about how the treatment affects the underlying progressive neurodegeneration. As a result, while there are treatments that improve symptoms, they become less effective as the neurodegeneration advances. The new study could remedy this issue by providing researchers with measurable targets, called biomarkers, to assess whether a drug slows or even stops the progression of the disease in the brain.
“For decades, the field has been searching for an effective biomarker for Parkinson’s disease,” said Debra Babcock, M.D., Ph.D., program director at the NIH’s National Institute of Neurological Disorders and Stroke (NINDS). “This study is an example of how brain imaging biomarkers can be used to monitor the progression of Parkinson’s disease and other neurological disorders.”
“The Parkinson’s Disease Biomarkers Program is an essential part of moving towards the development of treatments that impact the causes, and not just the symptoms, of Parkinson’s disease,” added NINDS program director Katrina Gwinn, M.D.
Dr. Vaillancourt’s team used functional magnetic resonance imaging (fMRI) to measure activity in a set of pre-determined brain areas in healthy controls, individuals with Parkinson’s disease, and patients with two forms of “atypical Parkinsonism” – multiple systems atrophy (MSA) and progressive supranuclear palsy (PSP) – that have symptoms similar to those of Parkinson’s disease. The researchers selected the specific brain regions, which are critical for movement and balance, based on the findings of past studies in people with these three conditions. The participants each underwent two scans spaced a year apart, during which they completed a test that gauged their grip strength.
A new study has found that neural activity in certain brain areas declines over time in individuals with Parkinson’s disease and two related syndromes. NeuroscienceNews.com image is credited to David Vaillancourt, Ph.D., University of Florida.
The healthy controls showed no changes in neural activity after a year, whereas the participants with Parkinson’s showed reductions in the response of two brain regions called the putamen and the primary motor cortex. Previous research had shown reduced activity in the primary motor cortex of Parkinson’s patients, but the new study is the first to suggest that this deficit worsens over time. Activity decreased in MSA patients in the primary motor cortex, the supplementary motor area, and the superior cerebellum, while the individuals with PSP showed a decline in the response of these three areas and the putamen.
Dr. Vaillancourt’s team now hopes to use its newly discovered biomarkers, in addition to one it had previously identified, to test whether an experimental medication known to improve Parkinson’s symptoms also slows the progression of those brain changes.
“These markers allow us to evaluate disease-modifying therapeutics because we know that the control group doesn’t change over a year but patient groups do,” Dr. Vaillancourt explained. “We can see whether a therapeutic prevents that change from occurring, and if it does, then that suggests it might have a disease-modifying effect.”
Funding: The study was supported by the NIH (NS052318, NS075012, NS082168).
Image Source: This NeuroscienceNews.com image is credited to David Vaillancourt, Ph.D., University of Florida.
Original Research:
Abstract for “Functional MRI of disease progression in Parkinson disease and atypical parkinsonian syndromes” by Roxana G. Burciu, PhD, Jae Woo Chung, MSc, Priyank Shukla, PhD, Edward Ofori, PhD, Hong Li, PhD, Nikolaus R. McFarland, MD, PhD, Michael S. Okun, MD and David E. Vaillancourt, PhD in Neurology. Published online July 15 2016 doi:10.1212/WNL.0000000000002985
http://neurosciencenews.com/parkinsons-brain-activity-4847/
Best and Worst of Neuroscience and Neurology – July 2016
Viatcheslav Wlassoff, PhD
Aug. 13, 2016
Aug. 13, 2016
Hundreds
of articles published this month further advanced our knowledge of
neuroscience. Lots of new discoveries published in July relate to some of the
most fundamental processes in the brain that shape our daily life, as well as
to the practical problems doctors have to deal with on a regular basis. The
selection of articles presented here reflects my personal opinion about their
importance – there were many more interesting articles that simply could
not be covered by this short review.
In
the beginning of July, scientific community marked the birthday of Alfred
Gilman, who received the 1994 Nobel Prize in Physiology and Medicine for his
work on G-proteins. These days, the description of G-proteins and their
functions can be found in every textbook on physiology and neurology, as they
are heavily involved in the processes of intercellular communication. Even in
this review G-proteins are mentioned in relation to some recent findings.
THE
BEST
Breast-fed
pre-term infants develop higher IQ later in life
New
observational study on pre-term infants confirm the
importance of feeding them with breast milk. The infants who received
predominantly breast milk during the first 28 days of life had higher IQ and
better cognitive and motor functions at age 7. MRI study demonstrated that at
this age the breast-fed children had larger volume of deep nuclear grey matter,
which plays important role in signal processing and connecting different parts
of brain.
Mechanism
of Levodopa-induced dyskinesia uncovered
Levodopa
is essential for treating patients with Parkinson’s disease, but unfortunately
many patients develop undesirable side effects such as dyskinesia, involuntary
rapid repetitive movements, after several years on the drug. Researchers
have uncovered that
the development of dyskinesia is linked to the changes in methylation of
certain genes, as levodopa can change the expression of DNA methylases.
Methylation affects gene expression and results in altered amount of
corresponding proteins, thus disturbing the normal homeostasis. Experiments on
animals show that drug therapies aimed at amending the DNA methylation level
can reduced dyskinesia symptoms.
Slow
action of antidepressants explained
Most
commonly used antidepressant from the serotonin reuptake inhibitors family are
know to take up to 2 months to start producing positive effects in the patients.
Researchers have now discovered the molecular mechanism responsible for this
slow action. It turned out that in people with depression, the signalling
G-protein molecules involved in the response to the drug are bound to the lipid
rafts on the membranes of neurons where they cannot effectively participate in
the signalling response. The study point
to a potential approach that may improve the efficacy of antidepressants.
Anti-cancer
drug promising for treating Alzheimer’s disease
An
FDA-approved anti-cancer drug pazopanib, an inhibitor of tyrosine kinase, was shown to
reduce the level of phosphorylation of tau-protein, one of the key culprits in
the development of Alzheimer’s disease. In laboratory animals, the effect of
the drug led to the improved clearance of toxic proteins from the brain. The
drug is known to penetrate the blood-brain barrier and is effective in the
doses half of those used in cancer treatment. In addition, pazopanib causes few
side effects. The use of pazopanib in human subjects with Alzheimer’s requires
further investigations.
fMRI
helped to visualize brain activity during hypnosis
Hypnosis
gradually emerged as a promising form of psychotherapy, but our knowledge of
brain processes in hypnotized state is still remains in its infancy.
Researchers used fMRI to study the brain of people during hypnosis sessions.
They found that
in hypnotized people the activity of dorsal anterior cingulate is decreased,
the connectivity between dorsolateral prefrontal cortex and the insula is
increased, and the connectivity between dorsolateral prefrontal complex and the
default mode network is reduced. These changes reflect the reduced state of
worrying, increased brain control over processes in the body, and reduced
awareness of one’s actions. Interestingly, these changes were most prominent
only among highly hypnotizable people, which represent around 10% of general
population.
THE
WORST
Antibiotics
increase frequency of manic episodes in psychiatric patients
It
is well established that the composition of bacterial microbiome in the gut
influence the work of our brain – this phenomenon is referred to as the gut
brain axis. It appears that the connection is rather prominent in people with
psychiatric disorders. Recent study suggests
that people with serious mental illnesses such as bipolar syndrome,
schizophrenia or major depression, are more likely to experience manic episode
at the time when they are treated with antibiotics. Antibiotics are known to
disrupt the bacterial flora in the gastrointestinal tract. This disruption may,
in turn, lead to behavioural alterations. Researchers suggest that preventive
treatments minimizing the use of antibiotics in psychiatric patients may reduce
the frequency of manic episodes.
No
link between traumatic brain injury and Alzheimer’s disease
Large
number of previous studies reported association between traumatic brain injury
(TBI) and the development of neurodegenerative diseases such as Alzheimer’s
later in life. The study published
this month questions this conclusion. By analysing data from over 7,000 older
adults (the largest cohort for this kind of study reported so far), researchers
found a strong positive association between TBI and Parkinson’s disease, but no
association between TBI and either Alzheimer’s disease or dementia.
Further work is needed to establish the mechanisms of and the factors
influencing post-TBI neurodegeneration.
Potential
dangers of transcranial direct current stimulation (tDCS)
Transcranial
direct current stimulation (tDCS) is becoming a popular approach to enhance
brain functions. tDSC devices are simple, and the practice of
self-administering them grew in popularity in recent years. This trend alarms
researchers who warned in the open letter that such DIY approach may lead to
unintended consequences. The letter published
by scientists this month points to the fact that the method is still very new
and it is not even known how the stimulation causes positive effects. It is
also not clear how tDCS affects the surrounding areas of the brain that are not
directly targeted, and what are the effects of larger accumulated doses
administered over longer periods of time. The effectiveness of the method also
varies from person to person, and there is a possibility that small changes in
the electrode placement and frequency may lead to undesirable effects.
Link
betwen Alzheimer’s and brain blood vessels problems underestimated
Although
risk factors associated with dementia and Alzheimer’s disease are well studied,
the role of brain blood vessels received very little attention. Recent study demonstrated
that the importance of this factor was clearly underestimated. Atherosclerosis
(plaques in the larger brain arteries) and arteriolosclerosis (hardening of the
smaller artery walls) strongly correlate with the chances of having dementia.
Problems with blood vessels in the brain also correlated significantly with
reduced cognitive abilities and performance in memory tests.
Reduced
physical activity after menopause linked to changes in brain
Post-menopausal
women often experience weight gain. This was often explained by the changes in
hormonal status. New evidences,
however, suggest that this phenomenon is associated with brain changes, more
specifically with the reduction in dopamine signalling level. This leads to
decreased stimulation of pleasure centre and lack of motivation for being more
physically active. Activation of dopamine receptors may potentially reverse
this process.
Bibliography:
Mandy
B. Belfort, MD, MPH et al. Breast Milk Feeding, Brain Development, and
Neurocognitive Outcomes: A 7-Year Longitudinal Study in Infants Born at Less
Than 30 Weeks’ Gestation. The Journal of Pediatrics, July 2016
DOI: 10.1016/j.jpeds.2016.06.045
A.
Figge, K. L. Eskow Jaunarajs, D. G. Standaert. Dynamic DNA Methylation
Regulates Levodopa-Induced Dyskinesia. Journal of Neuroscience,
2016; 36 (24): 6514 DOI: 10.1523/JNEUROSCI.0683-16.2016
Samuel
J. Erb, Jeffrey M. Schappi, Mark M. Rasenick. Antidepressants
Accumulate in Lipid Rafts Independent of Monoamine Transporters to Modulate
Redistribution of the G protein, G?s. Journal of Biological
Chemistry, 2016; jbc.M116.727263 DOI: 10.1074/jbc.M116.727263
Monica
Javidnia, Michaeline Hebron, Hannah J Brown, Charbel E-H Moussa. Pazopanib
Is a Potential Therapeutic for Tauopathies. AAIC 2017, July 16-20,
London. Abstract ID: a8677.
Heidi
Jiang, Matthew P. White, Michael D. Greicius, Lynn C. Waelde, and David
Spiegel. Brain Activity and Functional Connectivity Associated with
Hypnosis. Cerebral Cortex, July 2016 DOI: 10.1093/cercor/bhw220
Robert
Yolken, Maria Adamos, Emily Katsafanas, Sunil Khushalani, Andrea Origoni,
Christina Savage, Lucy Schweinfurth, Cassie Stallings, Kevin Sweeney, Faith
Dickerson. Individuals hospitalized with acute mania have increased
exposure to antimicrobial medications. Bipolar Disorders, 2016;
DOI: 10.1111/bdi.12416
Paul
K. Crane, Laura E. Gibbons, Kristen Dams-O’Connor, Emily Trittschuh, James B.
Leverenz, C. Dirk Keene, Joshua Sonnen, Thomas J. Montine, David A. Bennett,
Sue Leurgans, Julie A. Schneider, Eric B. Larson. Association of
Traumatic Brain Injury With Late-Life Neurodegenerative Conditions and
Neuropathologic Findings. JAMA Neurology, 2016; DOI: 10.1001/jamaneurol.2016.1948
Rachel
Wurzman, Roy H. Hamilton, Alvaro Pascual-Leone, Michael D. Fox. An open
letter concerning do-it-yourself users of transcranial direct current
stimulation. Annals of Neurology, 2016; 80 (1): 1 DOI: 10.1002/ana.24689
Zoe
Arvanitakis, Ana W Capuano, Sue E Leurgans, David A Bennett, Julie A
Schneider. Relation of cerebral vessel disease to Alzheimer’s disease
dementia and cognitive function in elderly people: a cross-sectional study. The
Lancet Neurology, 2016; DOI: 10.1016/S1474-4422(16)30029-1
Young-Min
Park, Jill A. Kanaley, Jaume Padilla, Terese Zidon, Rebecca J. Welly, Matthew
J. Will, Steven L. Britton, Lauren G. Koch, Gregory N. Ruegsegger, Frank W.
Booth, John P. Thyfault, Victoria J. Vieira-Potter. Effects of
intrinsic aerobic capacity and ovariectomy on voluntary wheel running and
nucleus accumbens dopamine receptor gene expression. Physiology
& Behavior, 2016; 164: 383 DOI: 10.1016/j.physbeh.2016.06.006
Viatcheslav Wlassoff, PhD, is a scientific and medical
consultant with experience in pharmaceutical and genetic research. He has an
extensive publication history on various topics related to medical sciences. He
worked at several leading academic institutions around the globe (Cambridge
University (UK), University of New South Wales (Australia), National Institute
of Genetics (Japan). Dr. Wlassoff runs consulting service specialized on
preparation of scientific publications, medical and scientific writing and
editing.
http://brainblogger.com/2016/08/13/best-and-worst-of-neuroscience-and-neurology-july-2016/
Subscribe to:
Posts (Atom)